Serine protease inhibitors-tripeptoid analogs
AssigneeCortech, Inc.
InventorsAlbert C. Gyorkos, Lyle W. Spruce
Life of this patent
Estimating the term…
Abstract
The present invention relates to certain compounds comprising substituted oxadiazole, thiadiazole and triazole structures which are useful as inhibitors of serine proteases, including human neutrophil elastase (HNE). Compounds described herein are characterized by their relatively low molecular weight, high potency and selectivity with respect to HNE, and can be used to effectively prevent, alleviate or otherwise treat disease states characterized by the degradation of connective tissue by proteases in humans.
Claims29
A compound of the formula:
- ##STR34## wherein X and Y are each O, N, or S , provided that at least one of X or Y is N;
- R.sub.1 is (C.sub.5 -C.sub.12)aryl, (C.sub.5 -C.sub.12)arylalkyl, (C.sub.5 -C.sub.12)arylalkenyl, fused (C.sub.5 -C.sub.12)aryl-cycloalkyl, alkyl fused (C.sub.5 -C.sub.12)aryl-cycloalkyl or alkenyl fused (C.sub.5 -C.sub.12)aryl-cycloalkyl optionally comprising one or more heteroatoms selected from N, S, or non-peroxide O;
- and optionally substituted with alkyl, halo, haloalkyl, amino, alkylamino or dialkylamino;
- R.sub.2 and R.sub.3 are independently or together H or alkyl;
- A is a direct bond, --C(O)--, --NH--C(O)--, --S(O).sub.2 --, --OC(O)-- or --CH.sub.2 --;
- and
- R.sub.4 is H, alkyl or alkenyl;
- or cycloalkyl, aryl or arylalkyl optionally comprising one or more heteroatoms selected from N, O and S, provided that not more than three of the following conditions are satisfied:
- (i) X and Y are independently O or N,
- (ii) R.sub.1 is .alpha.,.alpha.-dialkylalkylaryl or .alpha.,.alpha.-dialkylalkyl fused aryl-cycloalkyl wherein the cycloalkyl group is optionally substituted with two or more O atoms;
- (iii) R.sub.2 and R.sub.3 are independently H or alkyl;
- (iv) --A--R.sub.4 are together an alkoxycarbonyl;
- and
- further provided that not more than two of the following conditions are satisfied:
- (i) at least one of R.sub.2 or R.sub.3 is hydrogen;
- (ii) R.sub.1 is selected from a phenyl, phenylalkenyl;
- or phenylalkyl optionally substituted with halogen, haloalkyl, amino, aminoalkyl, dialkylamino, alkyl;
- or from a heteroaryl, heteroarylalkyl or heteroarylalkenyl wherein the heteroaryl group is a monocyclic five or six membered ring containing one or two heteroatoms independently selected from O, S and N, and optionally substituted with halogen, haloalkyl, amino, aminoalkyl, dialkylamino, alkyl;
- and
- (iii) R.sub.4 --A-- is a structure of the formula:
- Ph--CH.sub.2 --O--C(O)--, where Ph is an unsubstituted phenyl group and C(O) represents a carbonyl group.
A compound of Methylsulfonyl-L-valyl-N-[1-(2-[5-tert-butyl-1,3,4-oxadiazolyl]carbonyl)-2 -(S)-methylpropyl]-L-prolinamide.
Dependencies are inferred from the claim text.